Real-time insights. Smarter decisions. Better trades.
🔍 Search Stocks 14 day Free Trial
ALTERITY THERAPEUTICS LIMITED (ATH)ASX AI Signals has generated 7 signals for ATH during the last 90 days, indicating strong trading activity and ongoing AI monitoring
Latest ATH Signals | |
| 29/06/2026 | SELL |
| 28/06/2026 | SELL |
| 27/06/2026 | SELL |
ATH Share Price | |
| Current Price | $0.670 |
| 52 Week High | $0.670 |
| 52 Week Low: | $0.007 |
| Trading at (% of 52 Week High) | 100.00% |
Alterity Therapeutics Limited (ASX: ATH) is a biotechnology company focused on developing treatments for neurodegenerative diseases, including Parkinson's disease and Gaucher disease. The company is working on advancing its pipeline of drug candidates to address these serious medical conditions.
The Pharmaceuticals, Biotechnology & Life Sciences sector on the ASX includes companies involved in the development, production, and commercialization of drugs, medical devices, and biotechnology products. This sector covers activities such as research and development of new medicines, genetic testing, and innovative healthcare technologies. Companies often work on treatments for diseases, including cancer, infectious diseases, and chronic conditions. The sector plays a crucial role in advancing medical science and improving patient care through innovation.
The SELL recommendation for ALTERITY THERAPEUTICS LIMITED (ATH) is supported by weak price momentum and potential sector headwinds. However, the relatively low market capitalization and volatility introduce some uncertainty, moderating the confidence level.
MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that a study MELBOURNE, Australia AND SAN FRANCISCO, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the Company’s Phase 2 Alterity Therapeutics was founded in Melbourne, Australia in 1997 under the name Prana Biotechnology. Focusing on treatments for neurodegenerative diseases, the firm hopes to disrupt current medical thought on these conditions, offering alternatives for patients with any prognosis. With offices in MLatest ALTERITY THERAPEUTICS LIMITED(ATH) News
Alterity’s ATH434 Prevents Loss of Brain Cells in Parkinson’s Disease Animal Model
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy
Want to Buy Alterity Therapeutics (ATHE) Stock? See This First.
Get access to daily BUY & SELL signals, advanced AI analysis, watchlists and email alerts.
14 Day Free Trial • Cancel Anytime • Founders Price $15/month
Start My Free Trial